The prevailing sentiment swirling around the biopharma sector is decidedly mixed. A survey conducted by RBC Capital Markets on investor views found that in the positive column investors are enthusiastic about the emergence of technology platforms such as gene therapy, cellular therapies and gene editing, but the industry's earnings report, while previously "viewed as a tailwind at the beginning of the year, it is now viewed as a headwind (perhaps after the lackluster 1Q and poor performance among large-caps)." Read More
The global biopharmaceutical sector brought in more than $15 billion to its collective coffers in the second quarter of the year, adding to the almost $23 billion it raised in the first quarter. According to BioWorld data, the $38 billion generated in the first half of the year overshadowed the $18.79 billion raised in the same period last year. The 2018 total now represents a significant record for the amount of cash that has been invested into the industry during a six-month period, beating by a wide margin the previous record established in 2015 when $27.2 billion was raised. Read More
